# the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More

> **NCT06622603** · PHASE4 · RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 59 (estimated)

## Conditions studied

- Gout
- Uric Acid

## Interventions

- **DRUG:** Febuxostat

## Key facts

- **NCT ID:** NCT06622603
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2027-02-19
- **Final completion:** 2027-08-19
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06622603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06622603, "the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06622603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*